<DOC>
	<DOCNO>NCT01634061</DOCNO>
	<brief_summary>This open label study abiraterone acetate combination BEZ235 abiraterone acetate combination BKM120 CRPC patient abiraterone acetate failure .</brief_summary>
	<brief_title>Phase Ib Abiraterone Acetate Plus BEZ235 BKM120 Castration-resistant Prostate Cancer ( CRPC ) Patients</brief_title>
	<detailed_description>A dose-escalation part first determine maximum tolerate dose ( MTD ) and/or recomended dose expansion ( RDE ) abiraterone acetate combination BEZ235 abiraterone acetate combination BKM120 CRPC patient abiraterone acetate failure . Subsequently , MTD and/or RDE combination investigate two expansion treatment group CRPC patient fail abiraterone acetate therapy .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>Adult male ≥ 18 year old Eastern Cooperative Oncology Group Performance Status ≤ 2 Patient must castrate level testosterone ( &lt; = 50 ng/dL 1.7 nmol/L ) . ( Castrate status must maintain continued GnRH analogue unless patient undergone surgical orchiectomy ) . Histologically cytologically confirm diagnosis advance metastatic prostate cancer . Advanced metastatic castrationresistant prostate cancer progression abiraterone acetate failure Patients 2 line prior chemotherapy include cytotoxic agent Discontinuation antiandrogen , antineoplastic investigational treatment &gt; = 4 week ( 6 week bicalutamide ) . Previous treatment PI3K pathway inhibitor ( e.g . PI3K , AKT , mTOR inhibitor ) , ketoconazole , CYP17 inhibitor ( exception AA ) , enzalutamide . Patient active uncontrolled symptomatic CNS metastasis Inadequately control hypertension ( e.g . systolic blood pressure &gt; =160 mmHg diastolic blood pressure &gt; =95 mmHg ) Patient QTcF &gt; 480 msec screen ECG ( use QTcF formula ) , short/long QT syndrome , history QT prolongation/Torsades de Pointes Patient impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption study drug Patient medically document history active major depressive episode , bipolar disorder ( I II ) , obsessivecompulsive disorder , schizophrenia , history suicidal attempt ideation , homicidal ideation ( e.g . risk harm self others ) Patients experience dose reduction and/or treatment interruption due abiraterone acetate relate toxicity ( i.e . serious AEs , AEs , liver toxicity abiraterone acetate treatment</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Castration-resistant prostate cancer , abiraterone acetate , BEZ235 , BKM120 , dose escalation , abiraterone acetate failure</keyword>
</DOC>